Navigation Links
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide
Date:2/25/2009

Restructuring efforts include the re-alignment of shared services, including Business Technology, and establishment of Pharmaceutical Governance and Medical Device Governance Committees

ROCKVILLE, Md. and PRINCETON, N.J., Feb. 25 /PRNewswire/ -- Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) have announced restructuring initiatives as part of the North American pharmaceutical organizations' ongoing efforts to become key growth drivers for Otsuka's pharmaceutical business worldwide. The announcement follows the recent appointment of Mark Altmeyer as President and Chief Executive Officer, OAPI, and Dean R. Haubrich, Ph.D., as Chairman, OAPI Board.

The restructuring changes include the establishment of two governance committees responsible for ensuring regulatory compliance, cross-functional information sharing, reporting, CEO advisory, and the evaluation of new ideas and business proposals. Comprised of senior leadership, the Pharmaceutical Governance Committee will oversee OAPI business activities and ensure the strong governance of the company, while the Medical Device Governance Committee will oversee the medical device and diagnostics business activities for OAPI.

OAPI and OPDC are also re-aligning shared services to increase efficiencies among the organizations, including re-structuring the human resources, risk management, business technology and brand strategy groups. In support of the company's business technology re-alignment and new information technology operating model, OAPI has appointed Robert Mack to Senior Vice President, Business Technology. In this role, Mack will provide executive leadership for the vision, direction, execution and effectiveness of Otsuka's Global Information Technology functions as well as its U.S. pharmaceutical affiliates.

"Otsuka's restructuring will increase efficiencies across OAPI and OPDC, resulting in a stronger infrastructure that supports the growing needs of the organization," said Mark Altmeyer, President and CEO, OAPI. "Energizing our North American operations will not only drive growth globally, but also increase our ability to attract top talent and establish strategic partnerships -- both critical factors for our long-term success."

OPDC will continue to be led by Taro Iwamoto, Ph.D. William Carson, M.D. will remain as Senior Vice President, Global Clinical Development, Robert McQuade, Ph.D. as Senior Vice President, Global Medical & Regulatory Affairs, and Behshad Sheldon as Vice President, Global Marketing.

OAPI plans to make additional investments in strengthening its infrastructure in the coming year, including the consolidation of sales groups into four business units: Oncology, Neuroscience, Hospital, and Medical Diagnostics and Devices.

About Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular, oncologic, and gastrointestinal therapeutic treatments. OAPI is dedicated to improving patients' health and the quality of human life. OAPI is part of the Otsuka Pharmaceutical Group of companies.

About Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development and Commercialization, Inc. is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world with a strong commitment to research and development in the areas of cardiovascular, gastrointestinal, respiratory, renal and neuroscience systems, and to treat cancer and ophthalmic disorders. OPDC is part of the Otsuka Pharmaceutical Group of companies.

OAPI and OPDC are subsidiaries of Otsuka America, Inc. (OAI), which is wholly owned by Otsuka Pharmaceutical Co., Ltd. (OPC).

About Otsuka Pharmaceutical Co., Ltd. (OPC)

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka -- people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment.

The Otsuka Pharmaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned 928.4 billion Yen (approx. US $9.2 billion) in annual revenues in fiscal 2007. For additional information, please visit www.otsuka.com.


'/>"/>
SOURCE Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
2. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
3. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
4. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
5. Americas Peanut Farmers to Travel to New York City to Meet Consumers, Work to Rebuild Trust in All Things Peanut
6. American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer
7. More Than Half of Americans Say Family Skimped on Medical Care Because of Cost in Past Year; Worries About Affordability and Availability of Care Rise
8. American Med Tech, Inc. Merger or Acquisition?
9. The Bold Leadership America Needs to Confront a Broken Healthcare System
10. American Lung Association Victory in Lawsuit Against EPA Gives New Opportunity to Protect Public Health From Deadly Air Pollutant
11. Prominent Chicago Gynecologists Launch Treatment Project To Raise Awareness Among African American Women of Non-Invasive Ultrasound Uterine Fibroid Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dianne Michael Insurance Agency, an ... County, is embarking on a charity drive with the aim of generating support ... orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
(Date:12/8/2016)... December 8, 2016 According to a new market ... Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart ... MarketsandMarkets, the global market, in terms of value, is projected to reach ... CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... , Dec. 8, 2016  Hanson Research, ... of dissolution testing and diffusion testing instruments for ... acquired by Teledyne Instruments, Inc. ("Teledyne"). The move ... line of precision testing instruments, as well as ... development of new products and services. ...
Breaking Medicine Technology: